Brought to you by 
Noxxon & Gruenenthal in drug discovery deal for chronic pain
13 Jul 1999
Executive Summary
Noxxon Pharma and Gruenenthal GMBH have signed an agreement in which Noxxon will apply its drug discovery technology to the latter company's biological target to develop a chronic pain therapeutic.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Noxxon & Gruenenthal in drug discovery deal for chronic pain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice